Business, energy, technology, markets and global industry news from Business News Today

CD123

PharmaDeviceNews CD123
Orum’s ORM-1153 is moving toward an approximately 42-patient Phase 1 study after FDA clearance, testing whether a CD123-targeting conjugate can selectively deliver a GSPT1 protein degrader into acute myeloid leukemia cells and translate targeted protein degradation into a new precision-oncology strategy. Representative image.
Pharma & Biotech

Orum takes ORM-1153 into human testing after FDA clears first-in-human AML study

Orum plans an approximately 42-patient Phase 1 study of ORM-1153 after FDA cleared the CD123-targeting conjugate to deliver a GSPT1 protein degrader into AML cells.

Read More
Representative image of oncology research and blood cancer diagnostics. AbbVie’s DECNUPAZ approval highlights how CD123-targeted antibody-drug conjugates could reshape treatment options for blastic plasmacytoid dendritic cell neoplasm.
Pharma & Biotech

How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN

Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.

Read More
Representative image of acute myeloid leukemia research, illustrating how Orum Therapeutics’ ORM-1153 AACR 2026 data are drawing attention to CD123-targeting degrader-antibody conjugates in AML.
Pharma & Biotech

Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention

Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.

Read More
Pharma & Biotech

How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML

Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.

Read More